Paricalcitol

Paricalcitol
Clinical data
Trade names	Zemplar
Other names	(1R,3S)-5-[2-[(1R,3aR,7aS)-1-[(2R,5S)-6-hydroxy-5,6-dimethyl-3E-hepten-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-cyclohexane-1,3-diol
AHFS/Drugs.com	Monograph
MedlinePlus	a682335
Pregnancy; category	AU: C; ;
Routes of; administration	Oral, Intravenous
ATC code	H05BX02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	72%
Protein binding	99.8%
Metabolism	Hepatic
Elimination half-life	14-20 hours
Excretion	Faeces (74%), urine (16%)
Identifiers
	IUPAC name (1R,3R,7E,17β)-17-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethylhex-2-en-1-yl]-9,10-secoestra-5,7-diene-1,3-diol;
CAS Number	131918-61-1 ;
PubChem CID	5281104;
IUPHAR/BPS	2791;
DrugBank	DB00910 ;
ChemSpider	4444552 ;
UNII	6702D36OG5;
KEGG	D00930 ;
ChEBI	CHEBI:7931 ;
ChEMBL	ChEMBL1200622 ;
CompTox Dashboard (EPA)	DTXSID4048640 ;
ECHA InfoCard	100.184.862
Chemical and physical data
Formula	C27H44O3
Molar mass	416.646 g·mol−1
	InChI InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1 ; Key:BPKAHTKRCLCHEA-UBFJEZKGSA-N ;
	(what is this?) (verify)

Paricalcitol (chemically it is 19-nor-1,25-(OH)₂-vitamin D₂. Marketed by Abbott Laboratories under the trade name Zemplar) is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic kidney failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D₂ (ergocalciferol).

It was patented in 1989 and approved for medical use in 1998.^[2]

^ ^a ^b ^c ^d ^e Cite error: The named reference MSR was invoked but never defined (see the help page).
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 452. ISBN 9783527607495.